Predicting patient responsiveness to serotonergic therapy
OwnerMichael L. Camilleri, Raul A. Urrutiainventors
Life of this patent
Estimating the term…
Abstract
Methods to predict a patient's responsiveness to 5-HT3 receptor antagonists are disclosed. The methods allow a clinician to predict a patient's responsiveness to 5-HT3 receptor antagonists by determining the correlation that exists between a genotype in the promoter region of the gene encoding a serotonin transporter protein and patient response to 5-HT3 receptor antagonist therapy. In addition, methods to treat patients suffering from diarrhea-predominant irritable bowel syndrome and methods to identify a patient population for inclusion in a 5-HT3 receptor antagonist clinical trial are disclosed.
Claims14
A method for predicting patient responsiveness to a 5-HT3 receptor antagonist, said method comprising:
- (a) determining genotype of the promoter region of said patient's 5-HTTP gene;
- and
- (b) correlating said genotype with patient responsiveness.
A method for treating a patient with diarrhea-predominant irritable bowel syndrome comprising:
- (a) obtaining a biological sample from said patient;
- (b) genotyping the promoter region of said sample's 5-HTTP gene;
- and
- (c) administering to said patient an effective amount of a 5-HT3 receptor antagonist if said patient has a long variant/long variant genotype in the promoter region of the 5-HTTP gene.
A method for identifying a patient population for inclusion in a 5-HT3 receptor antagonist clinical trial comprising:
- (a) obtaining a biological sample from a potential participant in said clinical trial;
- (b) genotyping the promoter region of the 5-HTTP gene contained within said biological sample;
- and
- (c) identifying said potential participant as suitable for inclusion in said patient population based on the presence of a long variant/long variant genotype in the promoter region of said potential participant's 5-HTTP gene.
Dependencies are inferred from the claim text.